Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 25/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: ClaimsFiler has alerted investors in Pacira BioSciences, Inc. of a deadline to file lead plaintiff applications in a class action lawsuit. The suit arises from alleged failures to disclose material information affecting stock value during the specified class period from August 2, 2023 to August 8, 2024. Following a patent infringement case ruling on Exparel, Pacira's stock price fell drastically by over 47%. This situation highlights ongoing legal and financial challenges for the company.

Market Sentiment Analysis

CONCERNS & RISKS

  • Pacira BioSciences is facing a class action lawsuit for failing to disclose material information during the class period.
  • The company's stock price fell over 47% after a court ruling invalidated a key patent related to their main product, Exparel.
  • The lawsuit could result in significant financial ramifications for investors involved.

Full Press Release Details

NEW ORLEANS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Pacira investors should visit us at https://claimsfiler.com/cases/nasdaq-pcrx-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything. On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

The deadline to file is March 14, 2025.

What is the Class Period for the Pacira lawsuit?

The Class Period is from August 2, 2023, to August 8, 2024.

Where can I find more information about the lawsuit?

Visit https://claimsfiler.com/cases/nasdaq-pcrx-1/ for details.

Why did Pacira's stock price drop significantly?

The stock dropped after the court ruled the patent for Exparel invalid.

Who should investors contact for legal advice?

Investors can call Kahn Swick & Foti, LLC at 844-367-9658.

Last updated: Feb 20, 2025